Shares of ADMA Biologics (ADMA) have lost over a third over their value over during the past three years. However, the stock has really turned around in 2019 after multiple positive developments, delivering a 92% gain during that time frame.
I'd lightly glanced at ADMA Biologics in the past, but chose to wait until regulatory risk was behind us before digging deeper. Thesis here was intriguing considering that ASCENIV alone is thought capable of doing $200 million in peak US sales and phase 3 data achieved both primary and secondary endpoints (our element